After the injection of the ApDC intravenously into MIA PaCa-2-bearing mice, the F base directed the binding of the ApDC with albumin, and the formulation of the albumin-ApDC complex promoted the ApDC accumulation in the tumor site, while the F-modified ApDC did not exhibit better in vivo inhibitory activity compared with either Nab-PTX or DPBS buffer, which may be caused by the relatively low administration dosage (2 mg/kg) and the large tumor volume (300 mm3) at the first-time injection. This evidence concerns the gene ALB and neoplasm.